Arcus Biosciences Reports Q4 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Should l Buy RCUS?
Source: seekingalpha
Arcus Biosciences Inc. saw its stock rise by 17.08% as it reached a 20-day high.
The company reported a Q4 GAAP EPS of -$0.89, beating expectations by $0.14, and generated $33 million in revenue, exceeding market expectations by $8.06 million. Despite a year-over-year revenue decline of 8.3%, the progress of its product pipeline, particularly the anti-TIGIT cancer drug Casdatifan, showcased at the J.P. Morgan Healthcare Conference, may have attracted investor interest.
The implications of the earnings report suggest that while revenue has declined, the company's ability to manage costs and highlight its pipeline could position it favorably in the eyes of investors, especially with ongoing developments in its drug research.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCUS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCUS
Wall Street analysts forecast RCUS stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 23.940
Low
14.00
Averages
27.44
High
44.00
Current: 23.940
Low
14.00
Averages
27.44
High
44.00
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcus (RCUS) Q4 2025 Earnings Call Transcript
See More
Arcus Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Arcus Biosciences reported a Q4 GAAP EPS of -$0.89, beating expectations by $0.14, indicating efforts in cost management despite still posting a negative profit.
- Revenue Performance: The company generated $33 million in revenue for Q4, an 8.3% year-over-year decline, yet exceeded market expectations by $8.06 million, suggesting a resilient market demand amid challenges.
- Market Reaction: Despite the revenue drop, Arcus showcased its product pipeline, particularly the progress of Casdatifan, at the J.P. Morgan Healthcare Conference, which may attract investor interest.
- Research Developments: The late-stage study for the anti-TIGIT cancer drug in collaboration with Gilead has been halted, a decision that could impact future R&D directions and funding allocations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades and downgrades are not detailed, the overall rating changes may prompt investors to reassess their positions, potentially affecting trading volumes and price fluctuations of the related stocks.
- Expected Market Reaction: Analyst rating adjustments typically elicit immediate market responses, and investors should monitor these changes to seize potential investment opportunities or mitigate risks.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors are encouraged to regularly check the analyst ratings page for the latest updates.
See More
Arcus Biosciences Grants Stock Options to Employees
- Stock Option Grant: Arcus Biosciences granted stock options totaling 16,650 shares to three new employees at an exercise price of $22.13 per share, reflecting the company's commitment to talent retention and motivation.
- Restricted Stock Units: The company also awarded 8,400 shares in restricted stock units, aimed at enhancing employee loyalty and long-term incentives, thereby promoting overall company growth.
- Inducement Plan Context: These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board in January 2020, aligning with the NYSE's
See More
Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
- Clinical Trial Advancement: Arcus is executing its ongoing PEAK-1 Phase 3 trial to establish casdatifan as the standard of care for clear cell renal cell carcinoma, with a goal of rapid patient enrollment to complete the study within 18 months.
- Data Presentation Plans: At least three data presentations for casdatifan are anticipated in 2026, including updated progression-free survival (PFS) data from the ARC-20 study involving 121 patients, to be showcased at a medical conference in February 2026.
- Financial Stability: With approximately $1 billion in cash and investments, Arcus expects to fund its operations until at least the second half of 2028, ensuring the continuity of its development plans.
- New Drug Development: Arcus aims to advance its first small molecule MRGPRX2 antagonist into clinical development in 2026, targeting chronic spontaneous urticaria, highlighting the company's strategic focus in the inflammation and immunology sector.
See More
Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million
- Share Sale: Arcus Biosciences President Juan C. Jaen sold 82,997 shares through indirect holdings for $2,050,598, representing 5.91% of total holdings, indicating a larger-than-usual disposition compared to historical trades.
- Holding Changes: Post-transaction, Jaen retains 367,220 shares directly while indirect holdings drop to 954,063 shares, reflecting a significant decrease in indirect ownership and changes in internal liquidity.
- Market Reaction: The sale occurred near the stock's one-year high, and shortly after, the company announced a clinical trial failure, leading to a 14% drop in stock price in a single day, highlighting market uncertainty about the company's future.
- Financial Position: Despite challenges, Arcus maintains approximately $1 billion in cash and has promising early results for its kidney cancer candidate, with critical data expected throughout 2026, potentially offering opportunities for investors.
See More
Arcus (RCUS) Q4 2025 Earnings Call Transcript
See More
Arcus Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Arcus Biosciences reported a Q4 GAAP EPS of -$0.89, beating expectations by $0.14, indicating efforts in cost management despite still posting a negative profit.
- Revenue Performance: The company generated $33 million in revenue for Q4, an 8.3% year-over-year decline, yet exceeded market expectations by $8.06 million, suggesting a resilient market demand amid challenges.
- Market Reaction: Despite the revenue drop, Arcus showcased its product pipeline, particularly the progress of Casdatifan, at the J.P. Morgan Healthcare Conference, which may attract investor interest.
- Research Developments: The late-stage study for the anti-TIGIT cancer drug in collaboration with Gilead has been halted, a decision that could impact future R&D directions and funding allocations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, indicating a shift in market sentiment that could influence investor decisions and market trends.
- Overview of Updates: While specific upgrades and downgrades are not detailed, the overall rating changes may prompt investors to reassess their positions, potentially affecting trading volumes and price fluctuations of the related stocks.
- Expected Market Reaction: Analyst rating adjustments typically elicit immediate market responses, and investors should monitor these changes to seize potential investment opportunities or mitigate risks.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors are encouraged to regularly check the analyst ratings page for the latest updates.
See More
Arcus Biosciences Grants Stock Options to Employees
- Stock Option Grant: Arcus Biosciences granted stock options totaling 16,650 shares to three new employees at an exercise price of $22.13 per share, reflecting the company's commitment to talent retention and motivation.
- Restricted Stock Units: The company also awarded 8,400 shares in restricted stock units, aimed at enhancing employee loyalty and long-term incentives, thereby promoting overall company growth.
- Inducement Plan Context: These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board in January 2020, aligning with the NYSE's
See More
Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
- Clinical Trial Advancement: Arcus is executing its ongoing PEAK-1 Phase 3 trial to establish casdatifan as the standard of care for clear cell renal cell carcinoma, with a goal of rapid patient enrollment to complete the study within 18 months.
- Data Presentation Plans: At least three data presentations for casdatifan are anticipated in 2026, including updated progression-free survival (PFS) data from the ARC-20 study involving 121 patients, to be showcased at a medical conference in February 2026.
- Financial Stability: With approximately $1 billion in cash and investments, Arcus expects to fund its operations until at least the second half of 2028, ensuring the continuity of its development plans.
- New Drug Development: Arcus aims to advance its first small molecule MRGPRX2 antagonist into clinical development in 2026, targeting chronic spontaneous urticaria, highlighting the company's strategic focus in the inflammation and immunology sector.
See More
Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million
- Share Sale: Arcus Biosciences President Juan C. Jaen sold 82,997 shares through indirect holdings for $2,050,598, representing 5.91% of total holdings, indicating a larger-than-usual disposition compared to historical trades.
- Holding Changes: Post-transaction, Jaen retains 367,220 shares directly while indirect holdings drop to 954,063 shares, reflecting a significant decrease in indirect ownership and changes in internal liquidity.
- Market Reaction: The sale occurred near the stock's one-year high, and shortly after, the company announced a clinical trial failure, leading to a 14% drop in stock price in a single day, highlighting market uncertainty about the company's future.
- Financial Position: Despite challenges, Arcus maintains approximately $1 billion in cash and has promising early results for its kidney cancer candidate, with critical data expected throughout 2026, potentially offering opportunities for investors.
See More
